Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-arm, Open-label, Single-center Clinical Trial of Surufatinib and Serplulimab Combined With Standard Chemotherapy (Platinum/Etoposide) in Neuroendocrine Carcinoma.

Next Previous
Trial Profile

A Single-arm, Open-label, Single-center Clinical Trial of Surufatinib and Serplulimab Combined With Standard Chemotherapy (Platinum/Etoposide) in Neuroendocrine Carcinoma.

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide (Primary) ; Platinum complexes (Primary) ; Serplulimab (Primary) ; Surufatinib (Primary) ; Cisplatin
  • Indications Gastrointestinal cancer; Neuroendocrine carcinoma
  • Focus Therapeutic Use
  • Acronyms UNIONEC

Most Recent Events

  • 04 Jun 2024 Status changed from not yet recruiting to recruiting.
  • 04 Jun 2024 Results (As of December 27, 2023, n=6) assessing Efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC apresented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 02 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top